bezafibrate has been researched along with Cardiovascular Diseases in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dohmen, K; Haruno, M; Tanaka, H | 1 |
| Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Bortoletto, MS; Petris, AJ; Souza, RK | 1 |
| Goldbourt, U; Lutski, M; Tanne, D; Weinstein, G | 1 |
| Benderly, M; Goldbourt, U; Goldenberg, I | 1 |
| Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL | 1 |
| Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kugiyama, K; Mishina, H; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Watanabe, K; Watanabe, Y; Yano, T | 1 |
| Bloomgarden, ZT; Drexler, A | 1 |
| Fisman, EZ; Tenenbaum, A | 1 |
| Catapano, AL; Norata, GD; Pellegatta, F | 1 |
| Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J | 1 |
| Malcolm, J; Meggison, H; Sigal, R | 1 |
| Fisman, EZ; Motro, M; Tenenbaum, A | 1 |
| Arnaout, A; Malcolm, J; Sigal, R | 1 |
| Vos, E | 1 |
| Seed, M | 1 |
| Criqui, MH | 1 |
| Ganotakis, ES; Jagroop, IA; Mikhailidis, DP; Papadakis, JA; Winder, AF | 1 |
| Durrington, P | 1 |
| Faergeman, O | 1 |
| Noacco, C; Taboga, C; Tonutti, L | 1 |
12 review(s) available for bezafibrate and Cardiovascular Diseases
| Article | Year |
|---|---|
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
Update on the use of fibrates: focus on bezafibrate.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Humans; Hypolipidemic Agents; Primary Prevention | 2008 |
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2009 |
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Topics: Animals; Bezafibrate; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
[Peroxisome proliferator activated receptors and cardiovascular disorders].
Topics: Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipoproteins, HDL; Lipoproteins, LDL; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Treatment Outcome; Triglycerides | 2003 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment | 2004 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Coronary Artery Bypass; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation | 2004 |
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Triglycerides | 2005 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopidogrel; Diabetic Angiopathies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Smoking Cessation; Ticlopidine | 2006 |
Triglycerides and cardiovascular disease. A focus on clinical trials.
Topics: Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypolipidemic Agents; Triglycerides | 1998 |
Hypertriglyceridemia and the fibrate trials.
Topics: Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Male; Risk; Triglycerides | 2000 |
2 trial(s) available for bezafibrate and Cardiovascular Diseases
| Article | Year |
|---|---|
Insulin Resistance and Future Cognitive Performance and Cognitive Decline in Elderly Patients with Cardiovascular Disease.
Topics: Aged; Bezafibrate; Cardiovascular Diseases; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Insulin Resistance; Linear Models; Longitudinal Studies; Male; Middle Aged | 2017 |
Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Triglycerides | 2010 |
8 other study(ies) available for bezafibrate and Cardiovascular Diseases
| Article | Year |
|---|---|
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; PPAR alpha; Prognosis; Renal Insufficiency; Retrospective Studies; Risk Factors; Uric Acid; Ursodeoxycholic Acid | 2013 |
[Public sector participation in the supply of dyslipidemia medication in a population-based study].
Topics: Adult; Aged; Bezafibrate; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Interviews as Topic; Male; Middle Aged; Prevalence; Public Sector; Simvastatin | 2016 |
Fibrate use in diabetes: new concepts.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents | 2011 |
Multitherapy for diabetes.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Pravastatin | 2006 |
Therapy and clinical trials.
Topics: Arteriosclerosis; Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins | 1996 |
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibric Acids; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged; Pilot Projects; Treatment Outcome | 1999 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents; Pantetheine; Pyrazines; Risk Factors | 1991 |